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vascular integrity and transduce signals.1 Pro‑
teoglycans participate in collagen modification, 
growth factor retention, and chemokine signal‑
ing.2 In vascular disease, ECM composition and 
INTRODUCTION The extracellular matrix (ECM) 
of vascular walls is a complex polymeric structure 
composed of proteoglycans (PGs), elastin, colla‑
gens, and various glycoproteins acting to preserve 
ORIGINAL ARTICLE
Proteoglycan / glycosaminoglycan and collagen 
content in the arterial wall of patients with 
end ‑stage renal disease: new indicators of 
vascular disease
Krzysztof Batko1, Marcin Krzanowski1, Mariusz Gajda 2, Paulina Dumnicka3, 
Agata Pietrzycka4, Danuta Fedak5, Karolina Woziwodzka1, Paulina Gołasa1, 
Marek Kuźniewski1, Jan A. Litwin2, Władysław Sułowicz1, Katarzyna Krzanowska1
1  Department of Nephrology, Jagiellonian University Medical College, Kraków, Poland
2  Department of Histology, Jagiellonian University Medical College, Kraków, Poland
3  Department of Medical Diagnostics, Jagiellonian University Medical College, Kraków, Poland
4  Department of Pharmacobiology, Jagiellonian University Medical College, Kraków, Poland
5  Department of Clinical Biochemistry, Jagiellonian University Medical College, Kraków, Poland
Correspondence to:
Katarzyna Krzanowska, MD, PhD, 
Department of Nephrology, 
Jagiellonian University Medical 
College, ul. Kopernika 15c, 
31-501 Kraków, Poland, 
phone: +48 12 424 78 00, 
email: kasiajanda@op.pl
Received: September 12, 2019.
Revision accepted: 
October 15, 2019.
Published online: October 15, 2019.
Pol Arch Intern Med. 2019; 
129 (11): 781-789
doi:10.20452/pamw.15022
Copyright by Medycyna Praktyczna, 
Kraków 2019
KEY WORDS
biomarkers, end ‑stage 
renal disease, 
glycosaminoglycans, 
plasminogen activator 
inhibitor 1, 
proteoglycans
ABSTRACT
INTRODUCTION The prevalence of cardiovascular (CV) comorbidity in patients with chronic kidney dis‑
ease (CKD) is high, particularly in end ‑stage renal disease (ESRD). There is an ongoing search for novel 
biomarkers of CV disease in this population.
OBJECTIVES We aimed to investigate the associations of matrix proteoglycans (PGs) and glycosaminogly‑
cans (GAGs), collagen, and arterial calcifications with selected serum and plasma markers of endothelial 
dysfunction, inflammation, oxidative stress, and bone turnover in patients with ESRD.
PATIENTS AND METHODS We enrolled 47 adult patients (32 men) with stage 5 CKD. The following parameters 
were investigated: fibrinogen, soluble thrombomodulin (sTM), plasminogen activator inhibitor 1 (PAI ‑1), 
stromal cell ‑derived factor 1α (SDF ‑1α), calcium (Ca), phosphate (Pi), intact parathormone, interleukin 6, 
high ‑sensitivity C ‑reactive protein (hs ‑CRP), ferric reducing ability of plasma, 2,2 ‑diphenyl ‑1‑picrylhydrazyl 
scavenging, ferric reducing ability of ascorbate in plasma, fetuin ‑A, fibroblast growth factor 23, osteopontin, 
osteoprotegerin, osteocalcin, transforming growth factor β (TGF ‑β), hepatocyte growth factor, secreted 
protein acidic and rich in cysteine, as well as matrix metalloproteinase 2. Radial artery specimens were 
stained with alizarin red for calcifications, alcian blue for PGs and GAGs, and sirius red for collagen.
RESULTS We observed positive correlations between PG and GAG, collagen, and calcification staining. 
The most intense (grade 3) alcian blue staining was significantly correlated with diabetes as well as 
higher levels of Ca × Pi product, hs ‑CRP, fibrinogen, SDF ‑1α, PAI ‑1, and sTM. However, PAI ‑1 was the only 
significant predictor of grade 3 alcian blue staining in a multiple logistic regression model adjusted for 
hemodialysis, Ca× Pi product, and hs ‑CRP levels.
CONCLUSIONS Coagulation disorders and endothelial dysfunction are the hallmarks of ESRD. The levels 
of SDF ‑1α, PAI ‑1, sTM, and fibrinogen may be novel predictors of early vascular wall alterations and 
may serve as CV risk markers.
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Cohort) has reported that elevated levels of tu‑
mor necrosis factor α and fibrinogen are indepen‑
dent predictors of CKD progression and may be 
useful in risk stratification.18
The aim of the present study was to determine 
the associations of several known and emerging 
biomarkers of inflammation, oxidative stress, en‑
dothelial dysfunction, and bone turnover with 
changes in matrix composition and calcifications 
of the radial arteries assessed morphologically in 
patients with stage 5 CKD.
PATIENTS AND METHODS In this cross ‑sectional 
study, we adopted a methodology similar to our 
previous investigations,6,19,20 which were con‑
ducted as part of a completed research initia‑
tive, designed by KK, at the Department of Ne‑
phrology of Jagiellonian University Medical Col‑
lege in Kraków, Poland. However, the assessment 
of alcian blue and sirius red staining of the arte‑
rial wall in relation to vascular morphology and 
a panel of biochemical parameters is unique to 
this study and has not been reported before.
Consecutive patients with CKD treated at the 
Department of Nephrology were screened for 
potential eligibility and recruited if they fulfilled 
the following inclusion criteria: stage 5 CKD and 
necessity to establish an arteriovenous fistula 
(AVF) access for hemodialysis (HD), which would 
enable sampling of radial artery fragments for 
further histological assessment. The exclusion 
criteria were as follows: active infection, positive 
hepatitis B or C virus tests, HIV infection, renal 
transplant, parathyroidectomy, and malignancy.
The study included 47 adult patients (15 wom‑
en, 32 men), of whom 19 were in predialysis 
stage while 28 were already undergoing HD with 
a short ‑term or permanent catheter. The charac‑
teristics and clinical profile of patients are shown 
in TABLE 1. Medical history included information 
on comorbidities, diabetes mellitus, hyperten‑
sion, dyslipidemia, current smoking status, du‑
ration of dialysis, and medication use. As part of 
a completed research project, surgeons collected 
specimens of radial artery tissue while establish‑
ing an autologous AVF. Following this procedure, 
a predefined set of laboratory markers of inflam‑
mation, oxidative stress, endothelial dysfunction, 
and bone turnover was assayed.
Histology Samples of radial arteries were collect‑
ed during AVF procedures. Staining with alizarin 
red for calcium deposits, alcian blue for matrix 
PGs and glycosaminoglycans (GAGs), and siri‑
us red for collagen was followed by microscopic 
evaluation. Brightfield images were obtained us‑
ing an Olympus DP ‑71 digital CCD camera with 
the Olympus AnalySIS FIVE software (Olym‑
pus, Tokyo, Japan). Blinded assessment was per‑
formed by an experienced histologist. The degree 
of vascular calcification was semiquantitatively 
evaluated according to the following scale: 0, no 
mineral content; 1, a few small dispersed concre‑
tions; 2, numerous small dispersed concretions; 
regulation are altered, as illustrated by the accu‑
mulation of PGs and smooth muscle cells in early 
atherosclerotic lesions.1 The role of ECM remod‑
eling in calcification has been increasingly rec‑
ognized. This is also associated with high cardio‑
vascular (CV) morbidity in chronic kidney disease 
(CKD),3,4 as there has been an ongoing search for 
biomarkers in CKD alone.5-7 Genovese et al8 re‑
cently proposed that the ECM, as the underlying 
site of fibrosis, should be investigated to identify 
biomarkers of ECM remodeling in renal disease.
Plasminogen activator inhibitor type 1 (PAI ‑1) 
is a molecule regulating the activity of plasmin, 
which dissolves fibrin and activates matrix me‑
talloproteinases (MMPs), known regulators of 
the ECM.9,10 Dysregulation of fibrinolysis may re‑
sult from an increased PAI ‑1 level, which has been 
linked to CV disease,11 insulin resistance, meta‑
bolic syndrome, and vascular abnormalities, in‑
cluding endothelial dysfunction and coagulation 
disorders.9 These processes are well recognized 
in the pathogenesis of CKD. Hemostatic mole‑
cules, including soluble thrombomodulin (sTM), 
a marker of endothelial injury, have been corre‑
lated with inflammation and surrogate markers 
of atherosclerosis.12 Enhanced PAI ‑1 production 
may also be involved in endothelial dysfunction 
and early atherogenesis.13 In 2017, a systematic 
meta ‑analysis confirmed the association between 
PAI ‑1 and coronary artery disease, independent of 
traditional CV risk factors.14 Taken together, co‑
agulation disorders seem to be closely associated 
with several processes affecting CV morbidity and 
may mediate known pathways of atherogenesis.
Chronic inflammation is another key player 
in CKD. In patients with renal failure, elevated 
C ‑reactive protein (CRP) levels and diabetes were 
demonstrated as independent risk factors for 
CV events.15 High CRP levels increase the risk of 
CV disease, irrespective of traditional risk fac‑
tors.16 Malyszko et al17 indicated that adipose tis‑
sue may also contribute to CV disease by releas‑
ing inflammatory molecules such as tumor ne‑
crosis factor α, adiponectin, and PAI ‑1. Recent‑
ly, the CRIC study (Chronic Renal Insufficiency 
WHAT’S NEW?
Recently, investigators have focused on the identification of novel predic‑
tors of chronic kidney disease and high cardiovascular risk, which remains 
a leading cause of mortality in renal patients. Previous reports indicated that 
the extracellular matrix is a dynamically changing structural network subject to 
alterations, for example, in proteoglycan and collagen content, even in the very 
early stages of vascular pathology. In this study, we investigated a popula‑
tion of uremic and hemodialyzed patients who are particularly susceptible 
to cardiovascular comorbidity. Using an extensive panel of established and 
emerging biomarkers as well as morphological assessment (semiquantitative 
histology), we reported significant associations within the unique milieu of 
renal failure. We identified several potential predictors (particularly plasminogen 
activator inhibitor 1) of alterations in matrix composition, which may reflect 
an initial stage of vascular disease. Our findings add to the current knowledge 
on promising markers in renal disease.
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Czech Republic); osteopontin, HGF, IL ‑6, TGF ‑β, 
SPARC, and MMP ‑2 (R&D Systems, Minneapo‑
lis, United States); osteocalcin (Metra / Quidel, 
San Diego, California, United States), and FGF‑
‑23 (Immunotopics Int., San Clemente, Califor‑
nia, United States). Serum thrombomodulin, SDF‑
‑1α, and PAI ‑1 levels in platelet ‑poor EDTA plas‑
ma samples were measured using commercially 
available ELISAs (sTM, Human Thrombomodu‑
lin/BDCA ‑3 Immunoassay, R&D Systems; SDF‑
‑1α, Human CXCL12/SDF1α Immunoassay, R&D 
Systems; and PAI ‑1, Human Serpin E1/PAI ‑1 Im‑
munoassay, R&D Systems).
Plasma was investigated for total antioxidant 
capacity, as determined by the ability of plasma to 
reduce Fe3+ to Fe2+, in accordance with the Ben‑
zie method.21 A DPPH radical scavenging assay 
was used to determine radical scavenging capac‑
ity of plasma, as described by Janaszewska and 
Bartosz.22 The FRAP level was measured using 
spectrophotometry.
Statistical analysis Quantitative data were re‑
ported as a number and percentage of patients, 
and qualitative data, as median (lower and upper 
quartiles). Correlations between ordinal variables 
were assessed using the Goodman and Kruskal 
γ coefficient. Contingency tables were analyzed 
with the χ2 test. Laboratory results were compared 
between the groups using the Mann –Whitney test 
or the Kruskal –Wallis analysis of variance. Lo‑
gistic regression was used to assess predictors of 
high ‑grade histological staining (ie, grade 3 alcian 
blue and grade 3 sirius red). The multiple logistic 
regression models were adjusted for HD status. 
The models included independent variables that 
were significantly associated with the outcome 
variable in a simple analysis. However, the vari‑
ables that were highly correlated (eg, hs ‑CRP and 
fibrinogen) were not included in a single model to 
avoid redundancy. The original qualitative vari‑
ables were included in the models (they were not 
categorized), and the odds ratios were reported 
for a 1 ‑unit increase. Results were considered sig‑
nificant at a P value of less than 0.05 in 2 ‑tailed 
tests. The Statistica 12 software was used for anal‑
ysis (StatSoft, Tulsa, Oklahoma, United States).
RESULTS Clinical characteristics of patients 
The basic clinical characteristics did not differ 
significantly between predialysis (uremic) pa‑
tients and those receiving HD. Hypertension and 
dyslipidemia were the most prevalent conditions, 
while approximately 25% of the patients had di‑
abetes (TABLE 1). The groups differed in terms of 
medication use. Statins, antiplatelet drugs, and 
diuretics were more commonly used in predial‑
ysis patients, while patients on HD more often 
used erythropoietin analogues (Supplementary 
material, Table S1).
Histological examination of radial arteries Radial 
artery sections were stained for PGs and GAGs (al‑
cian blue), collagen (sirius red), and calcifications 
3, larger granular concretions; and 4, large areas 
occupied by fused mineral deposits. Calcification 
was limited to the vascular media in all samples. 
The relative content of PGs and GAGs was also 
assessed semiquantitatively (staining intensi‑
ty grades, 1–3).
The reproducibility of the adopted method of 
histological analysis was documented and de‑
scribed elsewhere.19
Laboratory tests Serum and plasma samples were 
obtained from peripheral venous blood after over‑
night fasting. Procedures were performed prior 
to the scheduled surgery for AVF creation. For 
plasma samples, blood was collected into EDTA 
tubes and subsequently frozen at a temperature 
of −70°C and stored for further analysis.
In all patients, the following biochemical pa‑
rameters were assessed: creatinine, fibrinogen, 
sTM, PAI ‑1, stromal cell ‑derived factor 1α (SDF‑
‑1α), calcium (Ca), phosphate (Pi), intact par‑
athormone (iPTH), interleukin 6 (IL ‑6), high‑
‑sensitivity CRP (hs ‑CRP), ferric reducing abili‑
ty of plasma, 2,2 ‑diphenyl ‑1‑picrylhydrazyl scav‑
enging (DPPH), ferric reducing ability of ascor‑
bate in plasma (FRAP), fibroblast growth factor 
23 (FGF ‑23), osteopontin, osteoprotegerin, os‑
teocalcin, transforming growth factor β (TGF ‑β), 
hepatocyte growth factor (HGF), secreted protein 
acidic and rich in cysteine (SPARC), and MMP ‑2. 
Biochemical assays were performed with the use 
of automatized analyzers: Hitachi 917 (Hitachi, 
Osaka, Japan) and Modular P (Roche Diagnos‑
tics, Mannheim, Germany).
Markers of endothelial injury, inflammation, 
and mineral and bone disorder were investigat‑
ed with microplate enzyme ‑linked immunosor‑
bent assays (ELISA) using an ELX808 automat‑
ic reader (BIO ‑TEK® Instruments Inc., Winoos‑
ki, Vermont, United States). The following kits 
were applied: osteoprotegerin (BioVendor, Brno, 
TABLE 1 Demographic and clinical characteristics of patients with stage 5 chronic 
kidney disease
Parameter Predialysis 
patients 
(n = 19)
Hemodialysis 
patients  
(n = 28)
P value
Age, y 62 (56; 72) 60 (48; 74) 0.5
Male sex, n (%) 13 (68) 19 (68) 0.9
Maintenance HD duration, mo NA 5.5 (1.0; 27.0) NA
eGFR (MDRD), ml/min/1.73 m2 13 (10; 14) NA NA
BMI, kg/m2 27.1 (23.6; 30.9) 24.6 (21.9; 28.1) 0.08
Diabetes, n (%) 6 (32) 6 (21) 0.4
Hypertension, n (%) 18 (95) 22 (79) 0.2
Dyslipidemia, n (%) 12 (63) 14 (50) 0.5
Active smoking, n (%) 4 (21) 10 (36) 0.3
Data are presented as median (lower quartile; upper quartile) unless otherwise 
indicated.
Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration rate; 
HD, hemodialysis; MDRD, Modification of Diet in Renal Disease; NA, not applicable
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hs ‑CRP, fibrinogen, SDF ‑1α, PAI ‑1, and sTM 
(FIGURE 2), while PAI ‑1 was the only significant pre‑
dictor of grade 3 alcian blue staining in the multi‑
ple logistic regression model adjusted for HD sta‑
tus, Ca × Pi product, and hs ‑CRP levels (odds ratio, 
10.3; 95% CI, 1.08–99.9; P = 0.04). No significant 
correlations were observed for sirius red staining. 
In our previous research,6,23 we reported a posi‑
tive correlation for SDF ‑1α and sTM with grades 
1 to 3 of alizarin red staining (P = 0.002 and P = 
0.028, respectively) in an analysis that excluded 
patients with grade 0 and 4 of staining. However, 
patients with grade 4 staining showed relatively 
low concentrations of both markers. We did not 
observe other associations between the grade of 
alizarin red staining and the concentrations of 
the studied laboratory markers.
Association of histological staining intensity with co-
morbidities and medical treatment We observed 
a correlation between the intensity of histological 
staining and diabetes. Grade 3 alcian blue staining 
was more often observed in patients with diabe‑
tes than in those without (75% vs 21%; P = 0.04). 
Also calcifications detected by alizarin red (stain‑
ing grade 1 to 4) were more common in patients 
with diabetes than in nondiabetic patients (44% 
vs 4.5%; P = 0.002). No such correlation was ob‑
served in the case of sirius red staining for colla‑
gen. The intensity of alcian blue, sirius, and aliza‑
rin red staining was not correlated with dialysis, 
smoking status, dyslipidemia, or obesity. No signif‑
icant associations were observed between the use 
of medications and the results of alcian blue, sir‑
ius red, and alizarin red staining of the radial ar‑
tery samples (Supplementary material, Table S1). 
The use of statins was associated with higher fi‑
brinogen concentrations (Supplementary materi‑
al, Figure S1A), while the use of vitamin D was as‑
sociated with higher concentrations of osteopro‑
tegerin, FGF ‑23, and HGF (Supplementary mate‑
rial, Figure S1B–S1D). Moreover, diuretic treatment 
was associated with the lower levels of osteopontin 
(P = 0.01), FGF ‑23 (P <0.001), and IL ‑6 (P = 0.003).
(alizarin red) in the ECM. The distribution of 
staining grades in the study group is shown in 
TABLE 2. We observed positive correlations between 
the grades of the 3 stainings, with γ coefficients 
of 0.5 between alcian blue and sirius red stain‑
ing (P = 0.002; FIGURE 1A), 0.59 between alcian blue 
and alizarin red staining (P <0.001; FIGURE 1B), and 
0.38 between sirius red and alizarin red staining 
(P = 0.01; FIGURE 1C).
Associations between histological staining and lab-
oratory markers of hemostasis, endothelial dysfunc-
tion, bone turnover, and inflammation The differenc‑
es in studied laboratory markers between predi‑
alysis and HD patients are shown in TABLE 3. Pa‑
tients on HD had higher concentrations of se‑
rum creatinine, Ca × Pi product, FGF ‑23 (but not 
iPTH), osteopontin, and sTM. The remaining lab‑
oratory markers did not differ significantly be‑
tween groups.
Grade 3 alcian blue staining was significantly 
associated with higher levels of Ca × Pi product, 
TABLE 2 Semiquantitative assessment of matrix proteoglycans / glycosaminoglycans, 
collagen, and calcifications in the radial arteries of patients with chronic kidney disease
Staining Patients with stage 5 CKD 
(n = 47)
Proteoglycans and 
glycosaminoglycans (alcian 
blue staining)
Grade 1 16 (34)
Grade 2 27 (57)
Grade 3 4 (9)
Collagen (sirius red staining) Grade 1 10 (21)
Grade 2 24 (51)
Grade 3 12 (26)
No data 1 (2)
Calcification (alizarin red 
staining)
Grade 0 22 (47)
Grade 1 12 (26)
Grade 2 4 (9)
Grade 3 4 (9)
Grade 4 5 (11)
Data are presented as number (percentage).
FIGURE 1 Correlations of the grades of histological staining for matrix proteoglycans and glycosaminoglycans (alcian blue) with collagen (sirius red) 
(A) and calcification (alizarin red) (B); correlation of the grades of histological staining for collagen (sirius red) with calcification (alizarin red) (C)
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other authors reported that TGF ‑β elevates PAI ‑1 
expression, while PAI ‑1 knockdown was associ‑
ated with decreased ECM deposition.28 It seems 
that renovascular homeostasis requires an ade‑
quate balance of fibrinolysis, which may be im‑
paired by excessive or reduced PAI ‑1 levels. PAI‑
‑1 is thought to inhibit the modification of plas‑
minogen and pro ‑MMP to active forms, prevent‑
ing the proteolysis of ECM.29 Interestingly, Krag 
et al28 observed that decreased ECM deposits 
following PAI ‑1 knockdown were not associat‑
ed with altered protease activity, which may be 
caused by the difficulty in investigating the local 
microenvironment. In the context of our find‑
ings, PAI ‑1 may serve as a marker of the accu‑
mulation of vascular PGs and GAGs, owing to 
its alleged role in regulating matrix remodeling, 
which may occur independent of uremia, inflam‑
mation, and calcium imbalance. Correlations 
with markers of inflammation, endothelial in‑
jury, and coagulation may also reflect the detri‑
mental effects of these processes in ESRD rath‑
er than a shared pathomechanism.
Abundant GAGs in the ECM of renal arter‑
ies have been described in ESRD, and the topo‑
graphical proximity of intimal PGs and collagen 
was suggested to imply their close interaction.30 
In a rabbit model of arterial injury and healthy 
controls, Strauss et al31 reported that significant 
early vascular changes resulted in a several ‑fold 
increase in ECM levels of PGs, elastin, and colla‑
gen, while intimal and medial proliferation was 
only modest. The PG components of the ECM 
are involved in vascular cell migration and vas‑
cular wall remodeling through retention and in‑
teraction with chemokines, growth factors, and 
modified collagen.2 The present study demon‑
strated that matrix GAGs and PGs are positive‑
ly correlated with collagen deposits and medial 
calcifications. Moreover, high PG levels were re‑
ported in early vascular lesions, which coincid‑
ed with reduced collagen fibers.1 Similarly, we 
observed that an increase in the grade of alcian 
blue staining was significantly associated with 
a higher grade of Sirius red staining for collagen. 
Positive staining with alcian blue may facilitate 
the identification of early vascular lesions in pa‑
tients with CKD.
In the present study, the majority of radial ar‑
tery specimens showed low to moderate grades 
of staining for matrix PGs and collagen. Overall, 
calcifications were less advanced and present only 
in the media. Similarly, Ballanti et al32 observed 
that less advanced medial calcifications are most 
prevalent in kidney transplant recipients without 
diabetes, which emphasizes the significance of 
kidney disease itself. However, we observed in‑
creased radial artery calcification in patients with 
a higher content of PGs and GAGs as well as col‑
lagen. In a rabbit model of renal failure lasting 
9 months, increased PGs and calcifications were 
predominant in the media, while intimal lesions 
were limited to increased cellularity. Calcifica‑
tions were accompanied by the accumulation of 
DISCUSSION In this study, we reported a signifi‑
cant association between the Ca × Pi product, hs‑
‑CRP, fibrinogen, SDF ‑1α, sTM, and PAI ‑1 levels 
and high ‑grade alcian blue staining for matrix 
PGs and GAGs. These correlations with several 
established and emerging biomarkers involved in 
CKD and CV diseases may suggest their involve‑
ment in early changes of the ECM and vascular 
wall structure. PAI ‑1 was the only significant pre‑
dictor of grade 3 alcian blue staining in the mul‑
tiple logistic regression model adjusted for di‑
alysis status, Ca × Pi product, and hs ‑CRP lev‑
els. Increased PAI ‑1 levels have previously been 
identified in severe atherosclerotic lesions and 
have been reported to promote thrombosis.24,25 
However, the association of PAI ‑1 levels with 
CKD vasculopathy and medial calcification has 
not been extensively studied. In an experimen‑
tal model of arterial injury in atherosclerosis‑
‑prone, hyperlipidemic mice, PAI ‑1 knockdown 
was shown to reduce neointimal formation and 
improve clearance of mural thrombi.26 Hertig et 
al27 showed that PAI ‑1 deficiency leads to uncon‑
trolled activation of TGF ‑β, resulting in early 
glomerular injury in a murine model. However, 
TABLE 3 Biomarkers of coagulation, endothelial function, mineral metabolism, and 
inflammation among patients with stage 5 chronic kidney disease
Parameter Predialysis patients 
(n = 19)
Hemodialysis 
patients  
(n = 28)
P value
Creatinine, μmol/l 396 (258; 452) 511 (405; 571) 0.001
Fibrinogen, g/l 5.12 (4.34; 5.52) 4.73 (4.35; 5.77) 0.8
hs ‑CRP, mg/l 3.28 (2.14; 6.91) 7.95 (3.06; 19.00) 0.1
IL ‑6, pg/ml 2.94 (2.15; 4.18) 5.28 (1.86; 8.44) 0.2
TGF ‑β, ng/ml 6,44 (6.09; 8.63) 5.01 (4.17; 7.04) 0.2
HGF, ng/ml 1.80 (1.56; 2.37) 2.32 (1.68; 3.59) 0.1
PAI ‑1, ng/ml 1.54 (1.01; 2.35) 1.64 (0.74; 1.84) 0.4
sTM, ng/ml 16.4 (12.8; 17.6) 19.1 (14.2; 20.3) 0.04
SDF ‑1α, pg/ml 2894 (2666; 3155) 3001 (2643; 3314) 0.7
Ca × Pi, mmol2/l2 2.98 (2.91; 3.25) 3.69 (2.97; 4.24) 0.01
iPTH, pg/ml 306 (204; 457) 249 (153; 453) 0.5
FGF ‑23, RU/ml 487 (398; 877) 1095 (523; 5066) 0.03
Osteopontin, ng/ml 217 (207; 320) 357 (270; 588) 0.03
Osteoprotegerin, pmol/l 5.12 (2.81; 6.96) 8.23 (4.36; 12.66) 0.09
Osteocalcin, mg/ml 41.7 (27.1; 54.1) 42.0 (25.6; 79.5) 0.4
SPARC, ng/ml 108 (74; 159) 102 (74; 178) 0.8
MMP ‑2 ng/ml 214 (191; 270) 249 (191; 325) 0.4
FRAP, mmol/l 1.04 (0.64; 1.31) 0.75 (0.54; 0.90) 0.1
FRASC, μmol/l 49.0 (36.2; 57.3) 50.2 (43.8; 58.8) 0.5
DPPH, % 39.8 (35.0; 48.0) 40.3 (34.2; 55.1) 0.8
Data are reported as median (lower quartile; upper quartile). A P value of less than 0.05 
was considered significant.
Abbreviations: Ca, calcium; DPPH, 2,2 ‑diphenyl ‑1‑picrylhydrazyl scavenging; FGF ‑23, 
fibroblast growth factor 23; FRAP, ferric reducing ability of plasma; FRASC, ferric 
reducing ability of ascorbate in plasma; HGF, hepatocyte growth factor; hs ‑CRP, high‑
‑sensitivity C ‑reactive protein; IL ‑6, interleukin 6; iPTH, intact parathormone; MMP ‑2, 
matrix metalloproteinase 2; PAI ‑1, plasminogen activator inhibitor 1; Pi, phosphate; 
SDF ‑1α, stromal cell ‑derived factor 1α; SPARC, secreted protein acidic and rich in 
cysteine; sTM, soluble thrombomodulin; TGF ‑β, transforming growth factor β
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FIGURE 2 Correlations between the concentrations of calcium and phosphate (Ca×Pi) product and alcian blue staining grade (A); serum C ‑reactive 
protein (CRP) and alcian blue staining grade (B); serum fibrinogen and alcian blue staining grade (C); serum stromal cell–derived factor 1α (SDF ‑1α) and 
alcian blue staining grade (D); serum thrombomodulin and alcian blue staining grade (E); and serum plasminogen activator inhibitor 1 (PAI ‑1) and alcian 
blue staining grade (F). Data are shown as median, interquartile range (box), nonoutlier range (whiskers), and outliers (dots).
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surface. It has a potent anticoagulation activi‑
ty, shed into a soluble form in ESRD.42,43 In pa‑
tients on HD, elevated sTM levels were reported 
to reflect improved endothelial injury after kid‑
ney transplant.44 Widely prevalent and recurrent 
endothelial injury may lead to mobilization of 
endothelial progenitor cells from bone marrow, 
thus rebuilding the damaged vascular barrier in 
ESRD.45,46 Importantly, this response seems to 
be severely impaired in CKD. SDF ‑1, together 
with other angiogenic factors, has been impli‑
cated in the migration of endothelial progeni‑
tor cells.46 On the basis of correlations shown in 
our study, we postulate that matrix alterations 
may occur following chronic endothelial injury, 
inflammation, and altered mineral imbalance, 
and as such may constitute one of the process‑
es leading to vascular disease. Our findings are 
unique and may translate into clinical practice. 
Our preliminarily findings provide evidence for 
the usefulness of alcian blue staining, with fi‑
brinogen, PAI‑1, sTM, and SDF‑1α as predictors. 
They may warrant further longitudinal studies 
with hard outcomes not only in ESRD but also 
in other related vascular conditions.
Although predialysis and HD patients differed 
in terms of medication use, none of the medica‑
tions were associated with staining for PG and 
GAG, collagen, or calcifications. However, we 
observed several correlations between medical 
treatment and some of the biomarkers studied, 
but the analysis of these correlations is outside 
the scope of this paper.
Limitations An inherent limitation of the pres‑
ent study is its cross ‑sectional design. Causality 
cannot be determined in this exploratory study 
by comparison with literature and statistical anal‑
ysis alone. Moreover, we discussed the possible 
relationships between biomarkers that may be 
only indicators of coexistent processes in patients 
with renal failure, without any direct mechanis‑
tic link. Also, our morphological analysis can ap‑
pear crude when considering the complexity of 
alterations in local vascular microenvironments. 
Despite these limitations, our study constitutes 
a unique attempt to translate experimental re‑
search on ECM turnover and CKD biomarkers 
into inpatient clinical setting of ESRD. The cost‑
‑efficiency of imaging diagnostic procedures, such 
as the measurement of coronary artery calcifi‑
cation score, might be limited by financial con‑
straints. Nonetheless, our study provides the ba‑
sis for developing a validated panel of markers of 
CV risk in patients with CKD.
Conclusions Our study showed that SDF ‑1α, 
PAI ‑1, sTM, and fibrinogen may be novel risk 
markers of early changes in the arterial wall. 
They may be involved in the very early process‑
es of vascular remodeling and calcification in pa‑
tients with advanced kidney disease and can be 
used as simple markers of CV risk in daily clin‑
ical practice.
extracellular substance stained with alcian blue 
and of smooth muscle–like cells, with no evidence 
of inflammation or lipid retention.33 Subsequent 
studies demonstrated that increased alcianophil‑
ic extracellular substance was one of the earliest 
vascular changes in chronic renal failure models.34 
Together, these findings suggest that changes in 
the ECM can be useful in the monitoring of ear‑
ly vascular remodeling in ESRD, when the pro‑
cesses of inflammation and dyslipidemia are still 
subclinical.
In this study, we investigated whether in‑
creased PG and GAG content in the vascular 
wall, as evidenced by the highest grade of al‑
cian blue staining, is correlated with selected 
clinical data, comorbidities, and biomarkers of 
endothelial dysfunction, inflammation, oxida‑
tive stress, and bone turnover. It was hypothe‑
sized that systemic inflammation in CKD, ure‑
mic toxins, elevated phosphate and glucose lev‑
els, and imbalance of calcification inhibitors are 
involved in the pathogenesis of medial arteri‑
al calcification.35 Our results indicated an as‑
sociation between vascular matrix alterations 
and diabetes but not with dialysis, smoking sta‑
tus, medications, dyslipidemia, and obesity. In 
a study comparing patients with and without 
diabetes undergoing HD, calcifications were re‑
ported more frequently in patients with diabe‑
tes and were linked to poor glycemic control.36 
Our findings support the association of PG and 
GAG accumulation as well as medial arterial cal‑
cification with diabetes in ESRD, which may in‑
dicate shared and synergistic stimuli of injury. 
Indeed, Klein et al37 showed that long ‑term ex‑
posure to high glucose levels increases PG syn‑
thesis. Glycosaminoglycans in the arterial me‑
dia are also altered throughout the course of 
diabetes, but the process differs from that ob‑
served in atherosclerosis.38 However, the conse‑
quences of PG and GAG alterations in the vascu‑
lar wall have not yet been fully elucidated. Dis‑
ruption in the balance of versican and hyaluro‑
nan leads to impaired mechanical function and 
structural pro ‑proliferative changes to the inti‑
ma.39 High glucose levels can alter perlecan and 
increase the number of monocytes in the sub‑
endothelial matrix.40 More recent studies have 
shown GAGs to be involved in aortic calcifica‑
tion,41 which is linked to bone morphogenetic 
protein ‑2 signaling in conditions of high Pi ac‑
cumulation. In light of these findings, we pos‑
tulate that a shift in the balance of matrix PGs 
and GAGs may contribute to diabetic vascular 
complications in patients with ESRD.
This study provides evidence for a link be‑
tween increased PG and GAG content in the vas‑
cular wall and medial calcifications. This adds to 
our earlier report on the association between 
medial arterial calcification and SDF ‑1 and sTM 
levels.6,23 The levels of SDF ‑1 and sTM were also 
shown to be positively correlated with matrix 
alterations (high grade of alcian blue staining). 
Thrombomodulin is a PG lining the endothelial 
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